BMS Speeds Expansion Into Neuroscience With $14bn Karuna Buy

Schizophrenia Drug Approval Expected In September

 
• By Mandy Jackson

Bristol Myers Squibb will double its neuroscience portfolio from one to two drugs after it pays $330 per share for Karuna and its lead asset KarXT, accelerating the big pharma’s diversification plans.

Abstract human brain. Artificial intelligence new technology. Science futuristic background
Bristol will go from a few Phase II-ready neuroscience programs to multiple late-stage trials • Source: Shutterstock

More from Deals

More from Business